27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study.

David L Saltman,Matthew G Varga,Tyler J Nielsen,Nicole S Croteau,Heather M Lockyer,Amit L Jain,Gregory A Vidal,David R Hout,Brock L Schweitzer,Robert S Seitz,Douglas T Ross,David R Gandara

Clinical lung cancer（2022）

引用 2|浏览7

暂无评分

摘要

These data confirm the association of DetermaIO with ICI clinical benefit in NSCLC, and expand on previous studies by demonstrating that first line treated PD-L1≥50% patients can further be stratified by IO score to identify efficacy. Exploratory analysis suggested that the IO score identifies benefit in patients with poor PS.

查看译文

关键词

DetermaIO,ECOG Performance Status,Immune Checkpoint Inhibitor,Lung Cancer,Monotherapy,Tumor Immune Microenvironment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要